Bryan Serrels

Medicine · Health Sciences

29h-index3.7kcitations130works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell Adhesion Molecules Research(57), Protein Degradation and Inhibitors(26), Cellular Mechanics and Interactions(24), Angiogenesis and VEGF in Cancer(23), Peptidase Inhibition and Analysis(18)

Publications129 total

Figure 5 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Data from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Figures S1-S10 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Table S1 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Figure 4 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Figure 2 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Figure 3 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Table S1 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Figures S1-S10 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Table S2 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Table S2 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
Cancer Research·2024· 5 citedOpen Access
A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma
2024Open Access
Harnessing CD3 diversity to optimize CAR T cells
Nature Immunology·2023· 61 citedOpen Access
Supplementary Fig. S4 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
2023Open Access
Supplementary Fig. S2 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
2023Open Access
Supplementary Text from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
2023Open Access
Supplementary Fig. S5 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
2023Open Access
Supplementary Fig. S1 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
2023Open Access
Supplementary Fig. S5 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Margaret C. Frame(32), Adam Byron(15), Valerie G. Brunton(15), Neil O. Carragher(11), Alan Serrels(9), Alex von Kriegsheim(7), Marta Canel(7), Emma Sandilands(7), Owen J. Sansom(7), Andrew V. Biankin(7), David K. Chang(7), Kenneth G. MacLeod(7), Kairbaan Hodivala‐Dilke(6), Rosanna Upstill‐Goddard(6), Nigel B. Jamieson(6), John C. Dawson(6), Morwenna Muir(5), Amaya García-Muñoz(5), Hitesh Patel(4), Louise E. Reynolds(4)